Galena Biopharma Inc. (Nasdaq: GALE) will advance its GALE-401 into a pivotal Phase 3 clinical trial. Shares of the biopharmaceutical soared 42 cents to close at $2.38.
Galena Biopharma advances GALE-401 to Phase 3
December 28, 2016 at 18:27 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.